CN115279769A - N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 - Google Patents

N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 Download PDF

Info

Publication number
CN115279769A
CN115279769A CN202080084633.9A CN202080084633A CN115279769A CN 115279769 A CN115279769 A CN 115279769A CN 202080084633 A CN202080084633 A CN 202080084633A CN 115279769 A CN115279769 A CN 115279769A
Authority
CN
China
Prior art keywords
compound
present disclosure
disorder
disclosure provides
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080084633.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·T·布兰德
P·安德烈斯
P·I·弗拉霍瓦
坂口智彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Switzerland GmbH
Takeda Pharmaceutical Co Ltd
Original Assignee
Myovant Sciences GmbH
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myovant Sciences GmbH, Takeda Pharmaceutical Co Ltd filed Critical Myovant Sciences GmbH
Publication of CN115279769A publication Critical patent/CN115279769A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080084633.9A 2019-10-10 2020-10-09 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 Pending CN115279769A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913560P 2019-10-10 2019-10-10
US62/913560 2019-10-10
PCT/EP2020/078493 WO2021069711A1 (en) 2019-10-10 2020-10-09 Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea

Publications (1)

Publication Number Publication Date
CN115279769A true CN115279769A (zh) 2022-11-01

Family

ID=72852650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080084633.9A Pending CN115279769A (zh) 2019-10-10 2020-10-09 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式

Country Status (5)

Country Link
US (2) US12338249B2 (OSRAM)
EP (1) EP4041739A1 (OSRAM)
JP (1) JP2022551316A (OSRAM)
CN (1) CN115279769A (OSRAM)
WO (1) WO2021069711A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
EP4419530A1 (en) 2021-10-18 2024-08-28 Sumitomo Pharma Switzerland GmbH Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160829A1 (en) * 2003-01-29 2006-07-20 Nobuo Cho Thienopyrimidine compounds and use thereof
US20150266891A1 (en) * 2012-09-28 2015-09-24 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
CA3010509A1 (en) * 2016-01-11 2017-07-20 Janssen Pharmaceutica Nv Substituted thiohydantoin derivatives as androgen receptor antagonists
US20190224196A1 (en) * 2016-09-30 2019-07-25 Myovant Sciences Gmbh Treatment of prostate cancer
US20190262346A1 (en) * 2016-09-30 2019-08-29 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (OSRAM) 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
JP2859791B2 (ja) 1992-01-31 1999-02-24 吉富製薬株式会社 ４−ブロモメチルビフェニル化合物の製造法
JPH10298156A (ja) 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd 置換ハロメチルフェニルカルバミド酸エステル類の製造方法
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
JP2001316391A (ja) 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
WO2001064683A1 (en) 2000-02-29 2001-09-07 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
GB2361917A (en) 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002088044A (ja) 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd ４’−ブロモメチル−２−シアノビフェニルの製造方法
NZ531375A (en) 2001-09-04 2005-06-24 Akzo Nobel Nv Glycine-substituted thieno [2,3-d]pyrimidines with combined LH and FSH agonistic activity may be used to treat fertility disorders
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
EP1806053A1 (en) 2004-10-25 2007-07-11 Nihon Nohyaku Co., Ltd. Herbicide compositions for upland farming and control method
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
JP2010229098A (ja) * 2009-03-27 2010-10-14 Central Glass Co Ltd イソインドリン誘導体のａ型の結晶形の製造方法及びイソインドリン誘導体のａ型の結晶形
TWI508962B (zh) 2009-04-22 2015-11-21 Du Pont 氮雜環醯胺之固體形態
WO2015066482A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
FI3263110T3 (fi) 2015-02-26 2023-07-25 Takeda Pharmaceuticals Co Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita
JP2017088564A (ja) * 2015-11-13 2017-05-25 株式会社トクヤマ ミルタザピンの製造方法
EP3395811B1 (en) 2015-12-25 2020-05-13 Xuanzhu Pharma Co., Ltd. Crystals of quinazoline derivative and preparation method therefor
US20170275330A1 (en) 2016-03-28 2017-09-28 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
US20220220123A1 (en) * 2019-05-15 2022-07-14 Dr. Reddy's Laboratories Limited Amorphous and crystalline forms of relugolix
WO2021026011A1 (en) * 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
CN112390812A (zh) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
WO2021031148A1 (zh) 2019-08-21 2021-02-25 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
CN112552312B (zh) 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN113620972A (zh) 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
US20240287090A1 (en) 2021-09-15 2024-08-29 Cipla Limited Solid state forms of relugolix
CN115947734A (zh) 2021-10-09 2023-04-11 江苏希迪制药有限公司 瑞卢戈利溶剂化物的晶型及其制备方法
EP4419530A1 (en) 2021-10-18 2024-08-28 Sumitomo Pharma Switzerland GmbH Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023119333A1 (en) 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
IN202221021078A (OSRAM) 2022-04-08 2023-10-13
CN115417883B (zh) 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160829A1 (en) * 2003-01-29 2006-07-20 Nobuo Cho Thienopyrimidine compounds and use thereof
US20150266891A1 (en) * 2012-09-28 2015-09-24 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
CA3010509A1 (en) * 2016-01-11 2017-07-20 Janssen Pharmaceutica Nv Substituted thiohydantoin derivatives as androgen receptor antagonists
US20190224196A1 (en) * 2016-09-30 2019-07-25 Myovant Sciences Gmbh Treatment of prostate cancer
US20190262346A1 (en) * 2016-09-30 2019-08-29 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
丁志新;门靖;曹卫凯;贾庆仪;: "公斤级SKI2496关键中间体的合成工艺改进", 中国药学杂志, no. 20, 22 October 2018 (2018-10-22), pages 15 - 18 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法

Also Published As

Publication number Publication date
US20260042775A1 (en) 2026-02-12
US12338249B2 (en) 2025-06-24
US20220396582A1 (en) 2022-12-15
EP4041739A1 (en) 2022-08-17
WO2021069711A1 (en) 2021-04-15
JP2022551316A (ja) 2022-12-08

Similar Documents

Publication Publication Date Title
US12338249B2 (en) Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea
TWI870922B (zh) 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
CN111712484B (zh) 作为免疫调节的芳环衍生物及其制备方法和应用
JP7713934B2 (ja) Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形
JP7379641B2 (ja) Ｉｒａｋ阻害剤としてのピラゾールアミド化合物
KR20220042429A (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
JP7737153B2 (ja) Ｍａｓｐ－２阻害剤および使用方法
TW201643139A (zh) 作為組蛋白脫乙醯基酶抑制劑之３－螺環－６－異羥肟酸萘滿
CN105793248B (zh) 酞嗪酮衍生物及其制备方法
JP2019533687A5 (OSRAM)
CN104987324A (zh) 作为alk抑制剂的嘧啶衍生物
WO2023217064A1 (zh) 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用
TWI831088B (zh) 新型苯并氮雜卓螺環衍生物
TWI870449B (zh) 吡唑化合物，其配製物以及使用該化合物和/或配製物之方法
CN107848986A (zh) 哒嗪酮类化合物、其制备方法、药物组合物及用途
JP2002241368A (ja) 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO2023284807A1 (zh) 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
TWI399374B (zh) 新穎晶體形式及製備方法以及其醫藥組合物
CN113135970A (zh) 一种具有抗芽孢活性的化合物及其药用组合物
CN114644635B (zh) 三氮唑类三并环衍生物及其制备方法和应用
WO2020114477A1 (zh) 作为免疫调节剂的化合物及其制备方法和应用
WO2022192533A1 (en) Heterocyclic rip1 kinase inhibitors
HK40067104A (zh) 三氮唑类三并环衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Switzerland

Address after: Basel, SUI

Applicant after: Sumitomo Pharmaceutical Switzerland Ltd.

Country or region after: Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Basel, SUI

Applicant before: MYOVANT SCIENCES GmbH

Country or region before: Switzerland

Applicant before: TAKEDA PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20221101

RJ01 Rejection of invention patent application after publication